New vaccine aims to train immune system to fight childhood cancer
NCT ID NCT00911560
First seen Jun 08, 2026 · Last updated Jun 19, 2026 · Updated 3 times
Summary
This trial tests a bivalent vaccine designed to help the immune system recognize and attack neuroblastoma cells. The vaccine contains two antigens (GD2L and GD3L) found on neuroblastoma cells, plus an adjuvant (OPT-821) to boost the immune response. Participants also take oral β-glucan, a yeast-derived substance that may help white blood cells kill cancer. The study includes children with high-risk neuroblastoma who are in remission or have minimal residual disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
bivalent vaccine (GD2L and GD3L antigens linked to KLH) with OPT-821 adjuvant and oral β-glucan
What this could lead to
If successful, this vaccine could help the immune system target and kill neuroblastoma cells, potentially improving outcomes for children with high-risk disease.
What could go wrong
This is an early-phase trial (phase I/II) with a small number of participants, so results may not apply broadly. The vaccine may not trigger a strong enough immune response, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.